These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 696465

  • 21. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ, Aarons SF, Frances AJ, Brown RD.
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [Abstract] [Full Text] [Related]

  • 22. Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
    van Kempen GM, Janjua R, Roos RA.
    Clin Neurol Neurosurg; 1995 May; 97(2):131-3. PubMed ID: 7656485
    [Abstract] [Full Text] [Related]

  • 23. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
    Hamaue N, Minami M, Terado M, Hirafuji M, Endo T, Machida M, Hiroshige T, Ogata A, Tashiro K, Saito H, Parvez SH.
    Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA, Juorio AV, Berry MD, Zhu MY.
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [Abstract] [Full Text] [Related]

  • 25. [Monoamine oxidase inhibitors: prospects for the use in clinical practice].
    Evtushenko SK, Lutskiĭ IS, Efimenko VN, Kazarian NE.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002 Sep; 102(8):53-60. PubMed ID: 12233260
    [No Abstract] [Full Text] [Related]

  • 26. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J.
    Wien Med Wochenschr Suppl; 1986 Sep; 98():1-18. PubMed ID: 3097965
    [Abstract] [Full Text] [Related]

  • 27. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA, Zagorevskiĭ VA, Lopatina KI, Sokolova TV, Gankina EM.
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. On the mode of action of L-deprenyl in the human central nervous system.
    Riederer P, Youdim MB, Rausch WD, Birkmayer W, Jellinger K, Seemann D.
    J Neural Transm; 1978 Aug; 43(3-4):217-26. PubMed ID: 745014
    [No Abstract] [Full Text] [Related]

  • 34. Critical role of MAO inhibition in Parkinson's disease.
    Knoll J.
    Adv Neurol; 1987 Aug; 45():107-10. PubMed ID: 3103382
    [No Abstract] [Full Text] [Related]

  • 35. A benzylamine oxidase distinct from monoamine oxidase B--widespread distribution in man and rat.
    Lewinsohn R, Böhm K, Glover V, Sandler M.
    Biochem Pharmacol; 1978 Aug; 27(14):1857-63. PubMed ID: 708467
    [No Abstract] [Full Text] [Related]

  • 36. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
    Wiener HL, Hashim A, Lajtha A, Sershen H.
    J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
    [Abstract] [Full Text] [Related]

  • 37. [Use of iumeks in the combined therapy of parkinsonism patients ].
    Man'kovskiĭ NB, Karaban' IN, Mialovitskaia EA.
    Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.